Bevacizumab biosimilar(Shanghai Henlius)

SHANGHAI, April 16, 2025 /PRNewswire/ -- On April 15, 2025, Henlius (2696.HK) released the "2024 Environmental, Social, and Governance (ESG) Report" (hereinafter referred to as the "ESG Report" or "Report"). This marks the sixth consecutive year that the company has submitted an ESG-related report to global stakeholders, comprehensively showcasing Henlius' remarkable achievements and steadfast commitment across 5 key ESG pillars: Product, Talent, Environment, Society, and Corporate Governance. Together for Health Guided by patient needs, Henlius has consistently strengthened its R&D innovation. In 2024, R&D investment reached RMB1.8405 billion. To date, the company has successfully launched 6 products across about 50 countries and regions, benefiting over 750,000 patients. Henlius continues to focus on therapeutic areas such as oncology and autoimmune diseases, rapidly advancing about 50 pipeline molecules. The company has achieved broad coverage in high-incidence cancers such as lung cancer, colorectal cancer, gastric cancer, and esophageal squamous cell carcinoma. Additionally, it is actively developing 5 orphan drugs and rare disease treatments across multiple therapeutic areas, including oncology, chronic inflammatory, and neurological diseases. In terms of accessible healthcare, 5 of Henlius' products have been included in China's National Reimbursement Drug List (NRDL). Its trastuzumab biosimilar HANQUYOU has been covered by public health insurance in countries including China, the UK, France, and Germany. The PD-1 inhibitor HANSIZHUANG has been included in 118 provincial or municipal-level government-backed supplemental insurance programs (Huiminbao), making high-quality biologics more accessible. Furthermore, through collaborations with international partners such as Abbott and SVAX, Henlius is expanding into emerging markets like Latin America and the Middle East, bringing Chinese innovation to the world and improving global health. Together for Talent Growth Upholding a people-centric talent philosophy, Henlius is dedicated to building a diverse talent ecosystem. In 2024, women made up 53% of the workforce. The company released Diversity Policy and launched an internal platform called "H-Voice" to promote open, transparent communication and feedback channels. Henlius emphasized employee growth and development, supporting 144 employees in obtaining professional certifications. Through the online learning platform "Henlius Academy" and customized training programs, the company continues to build its talent pipeline and empower future development. In 2024, it reached an average training time of 70.37 hours per employee. In 2024, Henlius was recognized as one of HR Asia's Best Companies to Work for in Asia for the third consecutive year and was also awarded one of Universum's Most Attractive Employers for Chinese Students for the first time. Together for a Green Future Henlius understands the importance of green development and embeds environmental protection in its core values and practices. In 2024, the company invested RMB7.8445 million in environmental protection, up 26% year-over-year, underscoring its strong environmental commitment. Throughout the year, Henlius completed 230 lean improvement projects, achieving a 2.87% year-over-year reduction in comprehensive energy consumption, a 5.47% decrease in greenhouse gas emissions, and a 5.93% reduction in water consumption—contributing to cleaner air and water. The Songjiang Facility successfully passed ISO 14001:2015 environmental management system certification, a testament to its environmental standards in line with international best practices. Henlius also promoted green supply chain initiatives, with 80% of direct procurement suppliers signing on to green supply chain agreements, jointly advancing low-carbon transformation across the industry chain. Together for a Thriving Community Driven by its "patient-centric" public welfare philosophy, Henlius carried out numerous social care initiatives in 2024, with total charity donations reaching RMB134.84 million. The company continued its Breast Cancer Rural Healthcare Outreach Program, and hosted public awareness activities for breast cancer and International Lung Cancer Awareness Month, including a charity cycling event to promote healthy lifestyles and holistic patient care. In supply chain management, Henlius adopted BI systems to enhance transparency. 80% of its local suppliers are now introduced into its GMP system, resulting in approximately RMB55.65 million in procurement savings. This continuous effort drives cost reduction, efficiency improvement, and enhances the stability of the supply chain. Together for Stronger Governance Henlius builds its ESG strategy on a foundation of compliance and governance, supported by a four-tier ESG governance structure. In 2024, the company held 2 dedicated ESG meetings and hosted its first company-wide ESG Culture Month, further embedding ESG practices into its operations. Henlius remains committed to responsible operations, conducting 99 compliance training sessions with a total of 4,569 attendants, with 100% of employees signing the Compliance Commitment Letter. The commercial team received targeted responsible marketing training through 39 sessions with a total of 4,867 attendants. In 2024, Henlius filed 22 patent applications and got 10 invention or utility model patents granted. The company also passed the ISO 27001:2022 information security management system recertification. Driven by innovation, with accessibility as the goal, sustainability as the foundation, social responsibility as the driving force, and governance as the guarantee, Henlius continuously creates value for patients, employees, society, and the industry. Looking ahead, Henlius will stay true to its patient-centered mission, integrating ESG into its business development, and contributing more "Chinese strength" to global health to co-create a brighter future for human well-being. About Henlius Henlius (2696.HK) is a global biopharmaceutical company with the vision to offer high-quality, affordable and innovative biologic medicines for patients worldwide with a focus on oncology, autoimmune diseases and ophthalmic diseases. Up to date, 6 products have been launched in China, 4 have been approved for marketing in overseas markets, and 5 marketing applications have been accepted for review in China, the U.S. and the EU, respectively. Since its inception in 2010, Henlius has built an integrated biopharmaceutical platform with core capabilities of high-efficiency and innovation embedded throughout the whole product life cycle including R&D, manufacturing and commercialization. It has established global innovation centre and Shanghai-based commercial manufacturing facilities certificated by China, the EU and U.S. GMP. Henlius has pro-actively built a diversified and high-quality product pipeline covering about 50 molecules and has continued to explore immuno-oncology combination therapies with proprietary HANSIZHUANG (anti-PD-1 mAb) as the backbone. To date, the company's launched products include HANLIKANG (rituximab), the first China-developed biosimilar, HANQUYOU (trastuzumab, trade name: HERCESSI™ in the U.S., Zercepac® in Europe), a China-developed mAb biosimilar approved in China, Europe and U.S., HANDAYUAN (adalimumab), HANBEITAI (bevacizumab), HANSIZHUANG (serplulimab, trade name: Hetronifly® in Europe), the world's first anti-PD-1 mAb for the first-line treatment of SCLC, and HANNAIJIA (neratinib). What's more, Henlius has conducted over 30 clinical studies for 19 products, expanding its presence in major markets as well as emerging markets. SOURCE Henlius WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED

2024 Annual Results Highlights: Total revenue reached RMB192.14 billion; Industrial operation profit amounted to RMB4.9 billion; Total revenue generated by the four core subsidiaries amounted to RMB134.65 billion, accounting for 70.1% of the Group's total revenue; Total debt to total capital ratio was 52%; cash, bank balance and term deposits amounted to RMB106.34 billion; The proportion of overseas revenue rose to 49.3%, representing a year-on-year increase of 6.2%; Investment in technology innovation reached approximately RMB6.9 billion. HONG KONG, March 30, 2025 /PRNewswire/ -- Fosun International Limited (HKEX stock code: 00656, "Fosun International"), together with its subsidiaries ("Fosun" or the "Group"), today announced its annual results for the year ended 31 December 2024 (the "Reporting Period"). In 2024, Fosun pressed ahead with its strategy of "business streamlining and advancements and exits", while deepening its focus on the household consumption sector in the face of global economic fluctuations and market challenges. By leveraging globalization, innovation, and asset-light operations, the Group advanced the development of its core industries, resulting in stable overall operational fundamentals. During the Reporting Period, the Group's total revenue reached RMB192.14 billion. Its four core subsidiaries – Yuyuan, Fosun Pharma, Fosun Insurance Portugal, and Fosun Tourism Group ("FTG") – generated a total revenue of RMB134.65 billion, accounting for 70.1% of the Group's total revenue, supported by a solid asset base. During the Reporting Period, the Group's industrial operation profit reached RMB4.9 billion, demonstrating stable operational fundamentals. The Group's loss attributable to owners of the parent amounted to RMB4.35 billion, mainly due to a one-off non-cash loss during the Reporting Period. Excluding this significant one-off effect, the profit attributable to owners of the parent amounted to RMB0.75 billion. In 2024, Fosun's operating cash flow remained healthy and stable. The Group consistently optimized its asset portfolio. The signed asset divestment amounted to approximately RMB17.5 billion equivalent at the group level, and approximately RMB30.0 billion equivalent at the consolidated level, thereby further optimizing the balance sheet and building up liquidity buffer. As at the end of the Reporting Period, the Group's total debt to total capital ratio was 52.0%, cash and bank balance and term deposits amounted to RMB106.34 billion. Healthy debt ratios and abundant funds can strengthen the Group's resilience against external risks while enhancing its ability to capture investment opportunities. In November 2024, after an absence of three years, Fosun returned to the offshore USD bond market and successfully issued long duration USD bonds, substantially expanding its offshore financing options. In terms of bank financing, Fosun refinanced its three-year unsecured syndicated loan with upsize from matured loan, achieving the successful launch of offshore syndicated loans for 8 consecutive years. Fosun High Technology issued several super short-term commercial papers, raising a total of RMB5.1 billion. In June 2024, the international credit rating agency S&P fully recognized the Group's steady improvement in credit matrix, and reaffirmed the BB- rating and a stable credit outlook. Guo Guangchang, Chairman of Fosun International, stated, "We believe that the clear strategic focus and robust industrial operational capabilities are the key to driving Fosun's long-term steady development. Looking ahead, we will further deepen our focus on core industries. By leveraging our globalization and innovation capabilities, we believe that we can create long-term, stable value for our shareholders, even in a challenging environment." Demonstrating ongoing success in globalization efforts As a global innovation-driven consumer group rooted in China, Fosun has continued to deepen its industrial presence in over 35 countries and regions, consolidating its global operational capabilities. In 2024, the Group's overseas revenue grew 6.2% year-on-year, increasing the proportion of overseas revenue to 49.3% of total revenue. High-quality global operations have become a new growth engine for Fosun. Benefiting from the forward-looking internationalization strategy, Henlius achieved overseas product sales revenue of RMB121 million in 2024, representing a substantial increase of 30.76% over the same period last year. HANSIZHUANG was approved for marketing in the European Union; HANQUYOU was approved for marketing in the U.S. and Canada, embarking on a new journey of commercialization in North America; HANLIKANG, the first biosimilar approved in China, was approved for marketing in Peru, Nicaragua and Bolivia; HANBEITAI was approved for marketing in Bolivia. Henlius now has four self-developed and self-manufactured products approved for overseas marketing, demonstrating ongoing success in its globalization efforts. In 2024, Fosun Insurance Portugal maintained its high-quality and sustainable growth, achieving growth in both domestic and international businesses with total gross written premiums reaching approximately EUR6,172 million. Both the combined ratio and revenue from the insurance business outperformed those of the same period in 2023. In addition, Fosun Insurance Portugal's overseas revenue reached EUR1.84 billion, fully demonstrating Fosun's capabilities of "global organization + local operations". Through overseas expansion, the proportion of international business increased from less than 5% in 2014 to 29.8%. In May 2024, Fosun entered into an agreement with ABN AMRO Bank N.V. to sell all of its equity interest in HAL, a leading private bank in Germany. Meanwhile, the Group will retain all the shares of Hauck & Aufhäuser Fund Services S.A. ("HAFS") indirectly held by HAL. HAFS plans to further expand its fund administration functions and create synergies with Fosun's operations in the financial and insurance sector in Europe. Since the initial investment in HAL in 2016, through continuous strengthening of industrial operations and ecosystem synergies, Fosun achieved an internal rate of return of nearly 14% on this investment up to the disposal. In the resources and energy business, Hainan Mining has continued its international expansion, expanding its oil and gas business, enriching its strategic metal reserves, and enhancing profitability. During the Reporting Period, Hannan Mining completed the acquisition of oil interests in four oil blocks in Oman and initiated the acquisition of two producing zirconium-titanium mines in Mozambique. As of March 2025, Phase I of the Bougouni lithium mine in Mali, Africa has achieved the conditions for continuous and stable production. In the cultural business, following the successful overseas debut in Paris, France in 2023, the Yuyuan Garden Lantern Festival has embarked on another overseas journey in 2025. In January 2025, the Yuyuan Garden Lantern Festival themed lantern installation made a stunning appearance in Hanoi, Vietnam, commemorating the 75th anniversary of the establishment of diplomatic relations between China and Vietnam. This year, it will also be featured in Thailand, continuing to showcase the charm of oriental culture globally. Leveraging technology innovation to enhance product strength Fosun regards technology innovation as a core strategic pillar and has established a global innovation system integrating "independent research and development ('R&D') + investment incubation + ecosystem collaboration". During the Reporting Period, the Group's investment in technology innovation amounted to approximately RMB6.9 billion. It has established more than 20 global technology innovation centers, covering various industries and fields, continuously fostering the launch of new technologies and products. In terms of R&D of innovative drugs, a total of 16 indications of 7 innovative drugs/ biosimilars independently developed or licensed-in by Fosun Pharma were approved for launch, including: Rabies vaccine (Vero cell) for human use (freeze dried) was approved for launch in Chinese mainland; and Trastuzumab for injection was approved for launch in the United States and Canada. As one of the first Hong Kong-listed "18A" pharmaceutical companies which turned to profit through product sales, Henlius successfully achieved sustained profitability in 2024 with a net profit of RMB820 million, representing a year-on-year increase of 50.3%. In terms of medical devices and medical diagnosis, the Ion Robotic Bronchoscopy ("Ion System") of Intuitive Fosun was approved by the National Medical Products Administration of the PRC; F-i6000 Automated Chemiluminescence Immunoassay Analyzer, F-C2000 Fully Automated High-Speed Chemiluminescence Analyzer, and Cytokine Detection Reagent (Chemiluminescence Method), which were independently developed by Fosun Pharma, were all approved for launch in Chinese mainland. Yuyuan has leveraged technology to empower traditional culture. This year's Yuyuan Garden Lantern Festival themed "Adventure of Mountain and Seas: The Jungle Chapter" leveraged VR technology to create the first immersive light and shadow exhibition featuring diverse landscapes inspired by "The Classic of Mountains and Seas" in China. It integrated AR live streaming, allowing tens of millions of viewers to participate in the exhibition online. Building on 30 years of experience, it showcased the transformation and upgrading of the traditional Spring Festival lantern festival into a modern urban cultural IP. Fosun Insurance Portugal has continued to build on its digital capabilities to drive the rapid growth of the insurance business. During the Reporting Period, the total number of digital users of Fosun Insurance Portugal exceeded 1.9 million, accounting for nearly 20% of Portugal's total population. Fosun is committed to deeply integrating AI technology into its diverse scenarios to drive innovation and enhance efficiency. For instance, Fosun Pharma launched the PharmAID decision intelligence platform, which integrates information extraction, patent insights, business forecasting, and more. With data updated at T+1, it supports accurate and efficient decision-making to accelerate and improve drug R&D. In addition, Sisram Medical is exploring the use of AI for precise skin analysis and personalized skin care solutions, etc. Focusing on core businesses with strategic advancements and exits, continuously amplifying the "flywheel effect" Fosun has continuously advanced its "business streamlining, and advancements and exits" strategy. While divesting some non-core assets, it has also focused on the development of core businesses to achieve "balanced investment and divestment". In 2024, Fosun Pharma increased its stake in Fosun Kairos to 100% to continuously focus on the R&D, manufacturing and commercialization of CAR-T cell therapy. In October 2024, the ULTRAMED Hainan project in Sanya was officially launched. It is set to create the world's first AI-themed resort by utilizing AIGC technology for guest room customization and introducing the digital human G.O (Gentle Organizer) service to enhance tourist experience. In addition, the Taicang Alps Resort Phase II project has been launched. It is developed by Taicang municipal government platform and managed by FTG. FTG also signed an asset-light operation agreement for the Jinsha Bay project in Shenzhen, marking the launch of the first Club Med in the Greater Bay Area. To achieve more effective resource allocation and drive sustainable value growth, Fosun has integrated its profound industry expertise, extensive investment experience, and high-quality commercial resources with the operations and investments of insurance companies, forming a three-dimensional "insurance + industry + investment" flywheel-driven strategy. Fosun's unique ecosystem synergy model has further amplified the flywheel effect. In 2024, it successfully implemented the "health care + insurance" ecosystem policy model, with 14,000 community health care policies sold, totaling premiums of RMB12.85 billion. Fosun Care achieved profitability for the first time, laying a solid foundation for flywheel development. As part of its strategic direction, Fosun made significant progress in asset-light operations in 2024. Fosun Pharma, together with the Shenzhen Guidance Fund and other investors, established a RMB5.0 billion biopharmaceutical industry fund to jointly promote the high-quality development of the pharmaceutical and healthcare industry in the Greater Bay Area, marking a significant milestone in the implementation of Fosun's asset-light strategy. Focusing on "Developing Business for Good" In 2024, Fosun centered on its corporate values of "Self-improvement, Teamwork, Performance, and Contribution to Society" to promote the deep integration of the ESG strategy and commercial value. It continuously contributed to global sustainable development through responsible investment, low-carbon transformation, and social initiatives. In addition, Fosun launched the "Create IMPACT" sustainable development strategy in 2024 to closely integrate commercial value with social value. Fosun's "Rural Doctors Program" was included in the "20 Cases of Private Sector's Sustainable Development in China for 20 Years" Report of the United Nations Global Compact. As at the end of 2024, the program had covered 78 counties in 16 provinces, municipalities and autonomous regions (including 21 key counties for national rural revitalization), assisted 15,000 administrative village clinics, supported 25,000 rural doctors, and benefited 16.34 million rural people in 3 million rural families. In terms of global public health cooperation, Fosun has actively participated in the "China-Africa Community Sustainability Action Network", contributing to the health development of African communities. Fosun Pharma has consistently contributed to the "China Solution", and announced that it would donate RMB10 million worth of artemisinin-based anti-malaria medicines to Africa in the next three years. As at the end of 2024, artesunate for injection independently developed by Fosun Pharma had been used to treat more than 80 million patients with severe malaria worldwide. Additionally, the company had supplied a cumulative total of over 400 million doses of artesunate for injection globally. During the Reporting Period, Fosun International maintained an MSCI ESG rating of AA, achieved an HSI ESG rating of AA-, ranked in the top 5% among global peers in S&P Global's Corporate Sustainability Assessment (CSA), and was selected as the top 1% in S&P Global's Sustainability Yearbook 2024 (China Edition) for its outstanding performance. Guo Guangchang, Chairman of Fosun International, said that Fosun is well-prepared to tackle challenges and pursue progress through "strategic advancements and exits", while continuing to deepen development in core industries. Looking ahead, the Group is confident in its ability to maintain steady development. SOURCE Fosun WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM? 440k+ Newsrooms & Influencers 9k+ Digital Media Outlets 270k+ Journalists Opted In GET STARTED